Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Scopolamine is a muscarinic receptor antagonist commonly used as a pharmacological model substance based on the “cholinergic hypothesis” of memory loss in senile dementia of the Alzheimer type. The objective of the study was to relate pharmacodynamic electroencephalogram (EEG) changes and scopolamine serum concentration using pharmacokinetic‐pharmacodynamic (PK‐PD) modeling techniques. This was a randomized, three‐way crossover, open‐label study involving 10 healthy nonsmoking young male volunteers who received either scopolamine 0.5 mg as an intravenous (IV) infusion over 15 minutes or an intramuscular (IM) injection oraplacebo. The pharmacodynamic EEG measure consists of the total power in delta, theta, alpha, and beta bands over frontal, central, and occipital brain areas. The values of the pharmacokinetic parameters of scopolamine after IV infusion were clearance (CL) 205 ± 36.6 L/h, volume of distribution (Vd) 363 ±66.7 L, distribution half‐life (t 1/2α) 2.9±0.67 min, and terminal half‐life (t 1/2β) 105.4 ±9.94 min (mean ± SEM). Mean peak serum concentrations (C max) were 4.66 and 0.96 ng/ml after IV and IM administration, respectively (p < 0.05). The area under the serum concentration versus time curve (AUC) after IM administration (81.27±11.21 ng/ml/min) was significantly lower compared to the value after IV infusion (157.28 ±30.86 ng/ml/min) (mean ±SEM, p < 0.05). Absolute bioavailability of scopolamine after IM injection was 57% ±0.08% (mean ±SEM). After both IV and IM administration, scopolamine induced a decrease in EEG alpha power (7.50‐11.25 Hz) over frontal, central, and occipital brain areas compared to placebo (p < 0.05). The individual concentration‐EEG effect relationships determined after IV infusion of scopolamine were successfully characterized by a sigmoidal E max model. The averaged values of the pharmacodynamic parameters were E 0 = 0.58 μV 2, E max = 0.29 μV 2, EC 50 = 0.60 ng/ml, and γ = 1.17. No time delay between serum concentrations and changes in alpha power was observed, indicating a rapid equilibration between serum and effect site. The results provide the first demonstration of a direct correlation between serum concentrations of scopolamine and changes in total power in alpha frequency band in healthy volunteers using PK‐PD modeling techniques. As regards the effect on the EEG, 0.5 mg of scopolamine administered IV appears to be a suitable dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Golding, J. F., & Stott, J. R. R. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00606.x · Cited by 99
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
EEG dynamics in patients with Alzheimer's disease
Jeong, J. (2004) · Clinical Neurophysiology · doi:10.1016/j.clinph.2004.01.001 · Cited by 1,337
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417
Pharmacokinetics and Pharmacodynamics in Clinical Use of Scopolamine
Renner, U. D., Oertel, R., & Kirch, W. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000168293.48226.57 · Cited by 314
Self-citationDrevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
Metadata
- Authors
- Ebert, U., Grossmann, M., Oertel, R., Gramatté, T., & Kirch, W.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 41
- Issue
- 1
- Pages
- 51-60
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2125999113
- Cited by
- 63
- References
- 2
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers. https://app.cochat.ai/papers/10.1177/00912700122009836
- The paper
- Ebert, U., Grossmann, M., Oertel, R., Gramatté, T., & Kirch, W. (2001). Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/00912700122009836
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.